全基因组测序技术在耐药肺结核诊断中的应用性评价

doi:10.19871/j.cnki.xfcrbzz.2024.03.004

摘要/Abstract

摘要： 目的评价全基因组测序技术在耐药肺结核诊断中的应用价值,为耐药肺结核的早期诊断提供参考。方法以2019年1月1日至2021年12月31日深圳市宝安区结核病定点医院确诊登记肺结核患者,痰培养阳性结核分枝杆菌菌株的8种抗结核药物表型药敏试验结果为金标准,将菌株全基因组测序的结果上传至SAM-TB结核分枝杆菌全基因组测序平台获得各菌株基因突变和耐药情况,比较各菌株基因组耐药的灵敏度、特异度、符合率和Kappa值,评价全基因组测序技术在耐药肺结核诊断中的应用价值。结果本次研究共纳入1327例培养阳性菌株,全基因组测序总体耐药率为20.35%（270/1327）。86.30%（233/270）的耐药菌株至少对异烟肼、利福平、乙胺丁醇或链霉素等4种一线抗结核药物中的1种耐药,一、二线抗结核药物耐药率最高的分别为链霉素（10.63%）和氧氟沙星（3.01%）。耐药菌株中,对异烟肼耐药的菌株主要发生了katG、fabG1、inhA和ahpC 4种基因突变,对链霉素和对氨基水杨酸耐药的菌株均产生了3种基因突变,对乙胺丁醇、卷曲霉素和氧氟沙星耐药的菌株均产生了2种基因突变,对利福平、卡那霉素耐药的菌株则各产生了1种基因突变。全基因组测序技术预测异烟肼、利福平耐药性的灵敏度、特异度均分别在93.44%（95%CI 84.05~98.18）、97.55%（95%CI 96.54~98.33）,对乙胺丁醇、链霉素耐药性预测的灵敏度分别为80.77%（95%CI 60.65~93.45）、70.18%（95%CI 62.72~70.92）,特异度分别为99.08%（95%CI 98.39~99.52）、98.18%（95%CI 97.24~98.87）;对4种二线抗结核药物耐药性预测的灵敏度在50%（95%CI 6.76~93.24）至100%（95%CI 88.42~100.00）之间,特异度均在98.86%（95%CI 98.13~99.36）及以上。结论全基因组测序技术对异烟肼、利福平和氧氟沙星等耐药肺结核诊断的灵敏度、特异度均较高,具有较高的临床应用价值。但对于卷曲霉素、链霉素、对氨基水杨酸等耐药肺结核的诊断价值仍需更多的研究加以证实。

关键词: 全基因测序, 耐药肺结核, 诊断, 应用性评价

Abstract: Objective To evaluate the application value of whole-genome sequencing technology to diagnostic the drug-resistant tuberculosis, and provide reference for the early diagnosis of drug-resistant tuberculosis. Method The phenotypic susceptibility results of 8 kinds of anti-tuberculosis drugs with sputum culture positive strains were regard as gold standard, which patients were confirmed and registered in the designated medical institution of Bao'an District from January 1, 2019 to December 31,2021. And the strains were inactivated before DNA was extracted for whole template sequence. The sequence results were uploaded to the platform to obtain the mutation sites of each strain. With reference to the drug resistance gene loci reported in previous literature, the sequence results were compared with the phenotypic drug susceptibility results, and the sensitivity, specificity,coincidence rate and Kappa value were used to evaluate the application value of whole-genome sequencing technology. Result The total drug resistance rate of 1327 culture-positive strains was 20.35%(270/1327). 86.30%(233/270) of the resistant strains were resistant to at least one of the four first-line anti-tuberculosis drugs, including isoniazid, rifampicin, ethambutol and streptomycin. The highest resistance rates of first and second-line anti-tuberculosis drugs were streptomycin(10.63%) and ofloxacin(3.01%). katG, fabG1,inhA and ahpC mutated genes were found in isoniazid-resistant strains. Three genetic mutations were found in resistant strains to streptomycin and para-aminosailcylic acid. Two genetic mutations were found in resistant strains to ethambutol, capreomycin and ofloxacin. There were only one genetic mutation in resistant strains to rifampicin and kanamycin.The sensitivity and specificity of whole-genome sequencing for predicting resistance to isoniazid and rifampicin were above 93.44%(95%CI 84.05-98.18), 97.55%(95%CI 96.54-98.33), respectively. The sensitivity and specificity of the whole-genome sequencing technology for predicting resistance to ethambutol and streptomycin was 80.77%(95%CI 60.65-93.45) and 70.18%(95%CI 62.72-70.92), 99.08%(95%CI 98.39-99.52) and 98.18%(95%CI 97.24-98.87), respectively. For the four second-line anti-tuberculosis drugs, the sensitivity of the whole-genome sequencing technology was from 50%(95%CI 6.76-93.24) to 100%(95%CI 88.42-100.00), the specificity was 98.86%(95%CI 98.13-99.36) or above. Conclusion The whole-genome sequencing technology has high application value in the diagnosis of drug-resistant tuberculosis for isoniazid, rifampicin, and ofloxacin, with the higher sensitivity and specificity. But more studies are needed to confirm it's diagnosis value to drug-resistant pulmonary tuberculosis for capreomycin, streptomycinand para-aminosailcylic acid.

Key words: Whole-genome Sequencing, Drug-resistant tuberculosis, Diagnosis, Applied evaluation

中图分类号:

R521

梅金周, 王云霞, 张梅娟, 桂静, 郑娟娟, 黄佩佩, 陈文胜, 郭艳芳. 全基因组测序技术在耐药肺结核诊断中的应用性评价[J]. 新发传染病电子杂志, 2024, 9(3): 16-20.

Mei Jinzhou, Wang Yunxia, Zhang Meijuan, Gui Jing, Zheng Juanjuan, Huang Peipei, Chen Wensheng, Guo Yanfang. Evaluation the application value of whole-genome sequencing technology to diagnosic the drug-resistant tuberculosis[J]. Electronic Journal of Emerging Infectious Diseases, 2024, 9(3): 16-20.

参考文献

[1] WORLD HEALTH ORGAINZATION.Global tuberculosis report 2022[R]. Geneva: World Health organization, 2022.
[2] LIU D, HUANG F, ZHANG G, et al. Whole-genome sequencing for surveillance of tuberculosis drug resistance and determination of resistance level in China[J]. Clin Microbiol Infect, 2022, 28(5):731.e9-731.e15.
[3] SHEA J, HALSE TA, LAPIERRE P, et al.Comprehensive Whole-Genome Sequencing and Reporting of Drug Resistance Profiles on Clinical Cases of Mycobacterium tuberculosis in New York State[J]. J Clin Microbiol, 2017, 55(6):1871-1882.
[4] 赵俊鹏,刘海涛,石凤玲,等. 结核分枝杆菌临床实验室诊断及耐药检测技术研究进展[J/CD].新发传染病电子杂志,2022, 7(3):78-83.
[5] 张洁, 任怡宣, 潘丽萍, 等. 全基因组测序在结核分枝杆菌研究中的应用[J]. 结核病与胸部肿瘤, 2020, 3:248-251.
[6] COHEN KA, MANSON AL, DESJARDINS CA, et al.Deciphering drug resistance in Mycobacterium tuberculosis using whole-genome sequencing: progress, promise, and challenges[J]. Genome Med, 2019, 11(1):45.
[7] WORLD HEALTH ORGAINZATION.The use of next generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide[R]. Geneva: World Health Organizaiton, 2018.
[8] 中华人民共和国国家卫生和计划生育委员会.肺结核诊断标准(WS 288—2017)[J/CD].新发传染病电子杂志,2018,3(1):59-61.
[9] 杨婷婷, 高谦. 构建基于全基因组数据的结核病耐药及传播监测网络[J]. 中国防痨杂志, 2021, 43(7):645-648.
[10] WALKER TM, KOHL TA, OMAR SV, et al.Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study[J]. Lancet Infect Dis, 2015, 15(10):1193-1202.
[11] PHELAN JE, O SULLIVAN DM, MACHADO D, et al. Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs[J]. Genome Med, 2019, 11(1):41.
[12] 陈燕梅, 温文沛, 吴惠忠, 等. 2016-2022年广东省结核病耐药监测结果分析[J]. 中国防痨杂志, 2022, 44(7):685-689.
[13] 林建, 林淑芳, 戴志松, 等. 2016-2019年福建省结核病耐药监测结果分析[J]. 中国防痨杂志, 2021, 43(9):924-928.
[14] 洪创跃, 杨婷婷, 李金莉, 等. 深圳市耐多药结核分枝杆菌耐药基因突变特征分析[J]. 中国防痨杂志, 2020, 42(6):583-589.
[15] CHE Y, LIN Y, YANG T, et al.Evaluation Of Whole-genome sequence to predict drug resistance of nine anti-tuberculosis drugs and characterize resistance genes in clinical rifampicin-resistant mycobacterium tuberculosis isolates from Ningbo, China[J]. Front Public Health, 2022, 10:956171.
[16] WU X, TAN G, SHA W, et al.Use of whole-genome sequencing to predictmycobacterium tuberculosis complex drug resistance from early positive liquid cultures[J]. Microbiol Spectr, 2022, 10(2):e251621.
[17] LI J, YANG T, HONG C, et al.Whole-genome sequencing for resistance level prediction in multidrug-resistant tuberculosis[J]. Microbiol Spectr, 2022, 10(3):e271421.
[18] XIAO Y, LIU K, LIN W, et al.Whole-genome sequencing-based analyses of drug-resistant mycobacterium tuberculosis from Taiwan[J]. Sci Rep, 2023, 13(1):2540.
[19] ENKIRCH T, WERNGREN J, GROENHEIT R, et al.Systematic review of whole-genome sequencing data to predict phenotypic drug resistance and susceptibility in swedish mycobacterium tuberculosis isolates, 2016 to 2018[J]. Antimicrob Agents Chemother, 2020, 64(5):e2519-e2550.
[20] NONGHANPHITHAK D, KAEWPRASERT O, CHAIYACHAT P, et al.Whole-genome sequence analysis and comparisons between drug-resistance mutations and minimum inhibitory concentrations of Mycobacterium tuberculosis isolates causing M/XDR-TB[J]. PLoS One, 2020, 15(12):E244829.